Lifeward Shuffles Leadership Amid Revenue Growth
Event summary
- Josh Hexter appointed Interim CEO of Lifeward effective September 1, 2026, succeeding Mark Grant.
- Rami Aviram named CFO, effective November 1, 2026.
- Q2 2026 revenue up 16% YoY to $6.6M, with ReWalk and AlterG products driving growth.
- Mark Grant departs after establishing commercial strategy, will consult through September 30, 2026.
- Hexter brings 30 years of life sciences leadership experience to the role.
The big picture
Lifeward's leadership transition comes as the company reports its strongest quarterly revenue performance since Q4 2024, driven by growth in its neurorehabilitation products. The appointments of Hexter and Aviram signal a focus on scaling the commercial business, but the company must now prove it can maintain momentum during this period of change. The strategic shift toward diversified biomedical solutions adds another layer of complexity to the leadership's immediate challenges.
What we're watching
- Execution Risk
- Whether Hexter can sustain the 16% YoY revenue growth amid leadership transition.
- Strategic Scaling
- How Lifeward will leverage its reimbursement infrastructure and distribution model to scale.
- Governance Dynamics
- The pace at which Lifeward identifies a permanent CEO and integrates new leadership.